Mid-Atlantic Biotherapeutics

Executive Summary

Mid-Atlantic Biotherapeutics (MABT) is a privately held biotechnology company headquartered in Rockville, Maryland, focused on developing novel oncology therapies. Founded in 2011, the company has recently announced the acquisition of XPose Therapeutics, a strategic move that expands its pipeline into the DNA Damage Response (DDR) space. This acquisition brings cutting-edge expertise in targeting previously undruggable DDR proteins, complementing MABT's existing immunotherapy platform. The combined entity aims to advance a portfolio of precision oncology programs, addressing significant unmet medical needs in cancer treatment. The acquisition marks a transformative milestone for MABT, positioning it to capitalize on the growing DDR therapeutic area and broaden its reach within the immuno-oncology landscape. Looking ahead, MABT is now focused on integrating XPose's assets and advancing key programs toward clinical development. Initial efforts will center on lead optimization and IND-enabling studies for the most advanced DDR-targeting candidates. The company is also expected to explore potential partnerships or collaborations to further its pipeline. While MABT remains private and has not disclosed financial details, the acquisition underscores its commitment to becoming a leader in precision oncology. The near-term success hinges on efficient integration and demonstration of preclinical proof-of-concept for the DDR portfolio.

Upcoming Catalysts (preview)

• Q4 2026Completion of XPose Acquisition Integration90% success
• H1 2027IND Filing for Lead DDR Program40% success
• Q2 2027Initial Preclinical Data Presentation for DDR Candidate60% success